日报更新时间：
周报更新时间：04-18 04:06
今开价：164.76
最高价：164.76
成交量：559380.0
昨收价：164.05
最低价：154.93
最新价：158.19
英文名称：Mirati Therapeutics
简介：Mirati Therapeutics,Inc.于2013年4月29日根据特拉华州法律注册成立，是一家临床阶段的生物制药公司，致力于开发针对性的肿瘤产品管道
电话：1-858-3323410
Mirati Therapeutics是一家临床阶段肿瘤学公司，在美国开发候选产品以解决癌症的遗传和免疫启动子问题。Mirati Therapeutics公司参与开发了一种光谱选择性激酶抑制剂Sitravatinib，该药物正处于治疗非小细胞肺癌（NCSLC）的 II 期临床阶段；以及用于治疗NCSLC患者Casitas B系淋巴瘤基因改变的 Ib 期临床试验；和用于NSCLC腺癌患者，结肠直肠癌患者和其他癌症的KRAS G12C抑制剂计划。Mirati Therapeutics还开发了mocetinostat，一种口服研究的选择性 I 类和 IV 类组蛋白去乙酰化酶抑制剂，已与Ourvalumab联合完成II期临床试验，用于治疗NSCLC。Mirati Therapeutics公司与BeiGene, Ltd.签订了合作和许可协议，以开发，生产和商业化sitravatinib。Mirati Therapeutics公司的临床阶段的候选产品包括： MGCD265，一种多标靶的激酶抑制剂，目前处于Ib临床开发试验阶段，用于治疗非小细胞肺癌和其他实体肿瘤，例如在胃中发现的癌症的和头颈部的鳞状细胞癌； MGCD516，一种激酶抑制剂，目前处于Ib临床开发阶段，用于治疗具有重视基因改变的实体肿瘤。 Mocetinostat，一种口服生物可利用的组蛋白脱乙酰酶抑制剂，目前处于II期临床试验阶段，用于膀胱癌、骨髓增生异常综合征和非霍奇金淋巴瘤患者，主要是弥漫性大B细胞淋巴瘤和滤泡性淋巴瘤。Mirati Therapeutics公司与Foundation Medicine, Inc.和Guardant Health, Inc.达成合作协议一起探索他们为了MGCD265作为伴随性诊断平台的开发和QIAGEN NV有合作伙伴关系，开发和商业化一项伴随性诊断测试来指导glesatinib (MGCD265)的使用，与一项用于非小细胞肺癌的标靶治疗正在开发。
| 交易日期 | 交易人 | 职位 | 类型 | 交易份额 | 价格 |
|---|---|---|---|---|---|
| 2017-01-25 | Braslyn Ltd. | Beneficial Owner of More than 10% Class | Buy | 28839 | 5.45 |
| 2017-01-25 | Braslyn Ltd. | Beneficial Owner of More than 10% Class | Buy | 19330 | 5.44 |
| 2017-01-24 | Braslyn Ltd. | Beneficial Owner of More than 10% Class | Buy | 30600 | 5.42 |
| 2017-01-23 | Braslyn Ltd. | Beneficial Owner of More than 10% Class | Buy | 27682 | 5.32 |
| 2017-01-22 | Braslyn Ltd. | Beneficial Owner of More than 10% Class | Buy | 19251 | 5.27 |
| 2017-01-19 | Braslyn Ltd. | Beneficial Owner of More than 10% Class | Buy | 23873 | 5.42 |
| 2017-01-18 | Braslyn Ltd. | Beneficial Owner of More than 10% Class | Buy | 21085 | 5.48 |
| 2017-01-17 | Braslyn Ltd. | Beneficial Owner of More than 10% Class | Buy | 16200 | 5.50 |
| 2017-01-16 | Braslyn Ltd. | Beneficial Owner of More than 10% Class | Buy | 17800 | 5.50 |
| 2017-01-12 | Braslyn Ltd. | Beneficial Owner of More than 10% Class | Buy | 52311 | 5.49 |
| 2017-01-11 | Braslyn Ltd. | Beneficial Owner of More than 10% Class | Buy | 49776 | 5.50 |
| 2017-01-05 | Braslyn Ltd. | Beneficial Owner of More than 10% Class | Buy | 581870 | 5.60 |
| 2017-01-05 | Boxer Capital L L C | Beneficial Owner of More than 10% Class | Buy | 280059 | 5.60 |
| 2017-01-05 | Boxer Capital L L C | Beneficial Owner of More than 10% Class | Buy | 6104 | 5.60 |
| 2016-06-13 | Baum (Charles M) | Chief Executive Officer | Buy | 20000 | 7.05 |
| 2016-06-08 | BAKER BROS ADVISORS L P | Beneficial Owner of More than 10% Class | Sell | 2318 | 9.56 |
| 2016-06-08 | BAKER BROS ADVISORS L P | Beneficial Owner of More than 10% Class | Sell | 158684 | 9.56 |
| 2016-06-08 | BAKER BROS ADVISORS L P | Beneficial Owner of More than 10% Class | Sell | 9056 | 9.56 |
| 2016-06-08 | BAKER BROS ADVISORS L P | Beneficial Owner of More than 10% Class | Sell | 19970 | 9.40 |
| 2016-06-08 | BAKER BROS ADVISORS L P | Beneficial Owner of More than 10% Class | Sell | 349919 | 9.40 |
| 2016-06-08 | BAKER BROS ADVISORS L P | Beneficial Owner of More than 10% Class | Sell | 5111 | 9.40 |
| 2016-06-07 | BAKER BROS ADVISORS L P | Beneficial Owner of More than 10% Class | Sell | 147529 | 9.21 |
| 2016-06-07 | BAKER BROS ADVISORS L P | Beneficial Owner of More than 10% Class | Sell | 2154 | 9.21 |
| 2016-06-07 | BAKER BROS ADVISORS L P | Beneficial Owner of More than 10% Class | Sell | 8417 | 9.21 |
| 2016-06-06 | BAKER BROS ADVISORS L P | Beneficial Owner of More than 10% Class | Sell | 275506 | 9.44 |
| 2016-06-06 | BAKER BROS ADVISORS L P | Beneficial Owner of More than 10% Class | Sell | 16493 | 9.44 |
| 2016-06-06 | BAKER BROS ADVISORS L P | Beneficial Owner of More than 10% Class | Sell | 16493 | 9.44 |
| 2016-06-06 | BAKER BROS ADVISORS L P | Beneficial Owner of More than 10% Class | Sell | 4201 | 9.44 |
| 2016-06-05 | Braslyn Ltd. | Beneficial Owner of More than 10% Class | Buy | 215151 | 10.31 |
| 2016-05-05 | Braslyn Ltd. | Beneficial Owner of More than 10% Class | Buy | 4500 | 17.15 |
| 第 页, 共 2 页 首页 上页 下页 末页 | |||||
| 机构持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| Fidelity SelectCo, LLC | 900044 | 2.29% | -179216 | -16.61% | 2019-07-31 |
| HHG PLC | 2034744 | 5.64% | 956022 | 88.63% | 2019-03-31 |
| Vanguard Group Inc | 2182038 | 6.05% | 750022 | 52.38% | 2019-03-31 |
| BlackRock Inc | 2336095 | 6.48% | 283146 | 13.79% | 2019-03-31 |
| Baker Bros Advisors LP | 2513462 | 6.97% | -- | -- | 2019-03-31 |
| Aviva Holdings Ltd | 3135966 | 8.70% | -- | -- | 2019-03-31 |
| venBio Select Advisor LLC | 3862500 | 10.72% | -935601 | -19.50% | 2019-03-31 |
| Fidelity Management and Research Company | 4021270 | 11.16% | 1861582 | 86.20% | 2019-03-31 |
| FMR Inc | 4606270 | 12.78% | 2409882 | 109.72% | 2019-03-31 |
| Fidelity Management & Research Company | 1900374 | 4.84% | -601850 | -24.05% | 2019-07-31 |
| Boxer Capital LLC | 1715560 | 4.76% | 150000 | 9.58% | 2019-03-31 |
| State Street Corporation | 1412039 | 3.92% | -119510 | -7.80% | 2019-03-31 |
| Vanguard Investments Australia Ltd | 900767 | 2.29% | 35121 | 4.06% | 2019-07-31 |
| Janus Capital Management LLC | 992144 | 2.52% | -146392 | -12.86% | 2019-07-31 |
| EcoR1 Capital, LLC | 1000000 | 2.77% | 352831 | 54.52% | 2019-03-31 |
| Cormorant Asset Management, LLC | 1075000 | 2.98% | -676699 | -38.63% | 2019-03-31 |
| BlackRock Fund Advisors | 1178915 | 3.00% | -46891 | -3.83% | 2019-07-31 |
| Perceptive Advisors LLC | 1164382 | 3.23% | 1038507 | 825.03% | 2019-03-31 |
| Jennison Associates LLC | 1192679 | 3.31% | -23785 | -1.96% | 2019-03-31 |
| Farallon Capital Management, L.L.C. | 1200000 | 3.33% | -100000 | -7.69% | 2019-03-31 |
| SSGA Funds Management Inc | 975269 | 2.71% | -888 | -0.09% | 2019-05-31 |
| Deerfield Management Co | 874486 | 2.43% | 33575 | 3.99% | 2018-12-31 |
| OppenheimerFunds Inc | 816810 | 2.32% | 291544 | 55.50% | 2018-12-31 |
| Bvf Inc | 723322 | 2.22% | -21678 | -2.91% | 2018-09-30 |
| PGIM Investments LLC | 666623 | 2.05% | 966 | 0.15% | 2018-12-31 |
| BlackRock Institutional Trust Company NA | 707717 | 2.18% | 253725 | 55.89% | 2018-06-30 |
| Broadfin Capital, LLC | 1020178 | 3.14% | -423770 | -29.35% | 2018-06-30 |
| Putnam Investment Management, LLC | 685225 | 2.11% | -212095 | -23.64% | 2018-10-31 |
| State Street Corp | 975822 | 3.02% | 278115 | 39.86% | 2018-06-30 |
| Marshall Wace North America LP | 804776 | 2.49% | 495017 | 159.81% | 2018-06-30 |
| Ghost Tree Capital, LLC | 500000 | 1.55% | 237500 | 90.48% | 2018-06-30 |
| Driehaus Capital Management LLC | 441470 | 1.37% | 441470 | -- | 2018-06-30 |
| Dimensional Fund Advisors, Inc. | 314306 | 0.97% | -20261 | -6.06% | 2018-06-30 |
| Invesco PowerShares Capital Mgmt LLC | 251986 | 0.72% | 790 | 0.31% | 2018-08-30 |
| Geode Capital Management, LLC | 271743 | 0.84% | 87337 | 47.36% | 2018-06-30 |
| Putnam Investment Management,LLC | 693567 | 2.39% | -246041 | -26.19% | 2018-03-31 |
| Janus Capital International Ltd | 170538 | 0.53% | 170538 | -- | 2018-06-30 |
| D. E. Shaw & Co LP | 284091 | 0.98% | -194392 | -40.63% | 2018-03-31 |
| Millennium Management LLC | 381924 | 1.32% | 381924 | -- | 2018-03-31 |
| Point72 Asset Management, L.P. | 407929 | 1.41% | 327030 | 404.24% | 2018-03-31 |
| OFI Global Asset Management, Inc. | 348880 | 1.08% | 348880 | -- | 2018-06-30 |
| Delaware Management Business Trust | 223630 | 0.77% | 143630 | 179.54% | 2018-03-31 |
| Prudential Investments LLC | 256805 | 0.88% | -- | -- | 2018-05-31 |
| Rock Springs Capital Management LP | 189000 | 0.65% | 9000 | 5.00% | 2018-03-31 |
| Longwood Capital Partners LLC | 155000 | 0.54% | 155000 | -- | 2017-12-31 |
| Bogle Investment Management L P | 137671 | 0.48% | 137671 | -- | 2017-12-31 |
| Royce & Associates, LLC | 121100 | 0.42% | -130000 | -51.77% | 2017-12-31 |
| Deutsche Asset & Wealth Management Investment GmbH | 80273 | 0.28% | 80273 | -- | 2018-01-31 |
| Morgan Stanley & Co Inc | 151319 | 0.61% | 150151 | 12855.39% | 2017-09-30 |
| Delaware Management Company | 215937 | 0.85% | 135937 | 169.92% | 2018-01-31 |
| Macquarie Investment Management Limited | 80000 | 0.32% | 80000 | -- | 2017-09-30 |
| PDT Partners, LLC | 68200 | 0.27% | 13500 | 24.68% | 2017-09-30 |
| SIMPLEX TRADING, LLC | 77903 | 0.31% | 77580 | 24018.58% | 2017-09-30 |
| Baker Bros Advisors Llc | 2549598 | 10.08% | 280400 | 12.36% | 2017-11-16 |
| JANE STREET GROUP, LLC | 57127 | 0.23% | 57127 | -- | 2017-09-30 |
| Northern Trust Investments N A | 53401 | 0.21% | 9036 | 20.37% | 2017-09-30 |
| Virtus ETF Advisers LLC | 19786 | 0.09% | -- | -- | 2017-12-28 |
| Goldman, Sachs & Co. | 98251 | 0.39% | 87858 | 845.36% | 2017-06-30 |
| Oxford Asset Management, LLC | 32181 | 0.12% | 32181 | -- | 2017-09-30 |
| Element Capital Management LLC | 107222 | 0.43% | 107222 | -- | 2017-06-30 |
| Sabby Management LLC | 255100 | 1.01% | 5365 | 2.15% | 2017-06-30 |
| Franklin Advisers Inc | 613996 | 3.08% | -- | -- | 2016-09-30 |
| Great Point Partners LLC | 227657 | 1.14% | 227657 | -- | 2016-09-30 |
| Sphera Funds Management Ltd. | 150000 | 0.75% | -- | -- | 2016-09-30 |
| RTW INVESTMENTS, LLC | 129129 | 0.65% | -1923 | -1.47% | 2016-09-30 |
| Renaissance Technologies Corp | 106800 | 0.54% | -128920 | -54.69% | 2016-09-30 |
| Deutsche Bank AG | 91952 | 0.46% | -8234 | -8.22% | 2016-09-30 |
| TIAA-CREF Investment Management LLC | 79147 | 0.40% | 28775 | 57.12% | 2016-09-30 |
| Franklin Advisers, Inc. | 842346 | 2.00% | 19079137 | 0.10% | 1999-11-30 |
| OrbiMed Private Investments IV,LP | 1267000 | 2.00% | 28697550 | 0.10% | 1999-11-30 |
| FMR LLC | 2172603 | 2.00% | 49209458 | 0.20% | 1999-11-30 |
| Baker Bros. Advisors, LLC | 2805074 | 2.00% | 63534926 | 0.20% | 1999-11-30 |
| Tavistock Life Sciences, LLC | 2930072 | 2.00% | 66366131 | 0.20% | 1999-11-30 |
| 共同基金持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| Vanguard Small Cap Value Index Fund | 514595 | 1.31% | 135885 | 35.88% | 2019-06-30 |
| Vanguard Total Stock Market Index Fund | 895509 | 2.28% | 35151 | 4.09% | 2019-06-30 |
| Vanguard Small Cap Index | 829334 | 2.11% | 235229 | 39.59% | 2019-06-30 |
| SPDR | 596738 | 1.52% | 9270 | 1.58% | 2019-07-31 |
| iShares Russell 2000 ETF | 549596 | 1.40% | 5550 | 1.02% | 2019-07-30 |
| iShares Russell 2000 Growth ETF | 229159 | 0.58% | 2712 | 1.20% | 2019-07-30 |
| Vanguard Extended Market Index Fund | 481197 | 1.22% | 5214 | 1.10% | 2019-06-30 |
| T. Rowe Price Health Sciences Fund | 440926 | 1.12% | 120800 | 37.74% | 2019-06-30 |
| Invesco Oppenheimer Global Fund | 440646 | 1.12% | -- | -- | 2019-06-30 |
| Fidelity | 251836 | 0.64% | -534 | -0.21% | 2019-04-30 |
| Janus Henderson Global Life Sciences Fd | 258805 | 0.66% | -1993 | -0.76% | 2019-06-30 |
| PGIM Jennison Health Sciences Fund | 339643 | 0.86% | -- | -- | 2019-06-30 |
| iShares Nasdaq Biotechnology ETF | 355840 | 0.91% | 3628 | 1.03% | 2019-07-30 |
| T. Rowe Price New Horizons Fund | 370507 | 0.94% | 129700 | 53.86% | 2019-06-30 |
| Janus Henderson Research Fund | 396367 | 1.01% | -- | -- | 2019-06-30 |
| Fidelity Advisor | 239020 | 0.66% | -45800 | -16.08% | 2019-05-31 |
| PGIM Jennison Small Company Fund | 246555 | 0.68% | -- | -- | 2019-05-31 |
| Franklin Biotechnology Discovery Fund | 248500 | 0.69% | -- | -- | 2019-05-31 |
| iShares US Small Cap ETF (CAD-Hedged) | 438643 | 1.22% | -738 | -0.17% | 2019-05-30 |
| Vanguard Small Cap Index Fund | 402460 | 1.12% | 4322 | 1.09% | 2019-04-30 |
| Oppenheimer Global Fund | 440646 | 1.22% | -- | -- | 2019-03-31 |
| Putnam Global Health Care Fund | 345911 | 0.96% | 345911 | -- | 2018-12-31 |
| Lord Abbett Developing Growth Fund | 210558 | 0.60% | -- | -- | 2019-02-28 |
| Delaware Healthcare Fund | 223630 | 0.63% | -- | -- | 2019-02-28 |
| Wells Fargo Discovery Fund | 211400 | 0.60% | -- | -- | 2019-01-31 |
| Candriam Eqs L Biotechnology | 211000 | 0.60% | -- | -- | 2019-01-31 |
| BlackRock Health Sciences Opps Port | 214050 | 0.61% | 138050 | 181.64% | 2019-01-31 |
| Janus Henderson Venture Fund | 155127 | 0.48% | 39635 | 34.32% | 2018-12-31 |
| Threadneedle American Smlr Coms Fd(US) | 147951 | 0.46% | 62944 | 74.05% | 2018-10-31 |
| Invesco DWA Healthcare Momentum ETF | 139257 | 0.43% | -- | -- | 2018-11-30 |
| Oppenheimer Global Fund/VA | 99073 | 0.30% | 34579 | 53.62% | 2018-10-31 |
| Prudential Jennison Health Sciences A | 316359 | 0.98% | -- | -- | 2018-07-31 |
| Oppenheimer Global A | 277633 | 0.86% | -- | -- | 2018-07-31 |
| Janus Global Life Sciences D | 297055 | 0.92% | 297055 | -- | 2018-06-30 |
| Delaware Healthcare A | 223630 | 0.69% | -- | -- | 2018-07-31 |
| iShares Russell 2000 Growth | 172862 | 0.52% | -167 | -0.10% | 2018-09-12 |
| Wells Fargo Discovery Admin | 150300 | 0.46% | 150300 | -- | 2018-07-31 |
| Fidelity Spartan | 142697 | 0.44% | -- | -- | 2018-07-31 |
| PowerShares DWA Healthcare Momentum ETF | 150579 | 0.46% | -- | -- | 2018-09-13 |
| PowerShares DWA SmallCap Momentum ETF | 123259 | 0.37% | -- | -- | 2018-09-13 |
| DFA US Micro Cap I | 78391 | 0.24% | -- | -- | 2018-07-31 |
| Oppenheimer Global VA Svc | 64494 | 0.20% | -1028 | -1.57% | 2018-07-31 |
| Vanguard Extended Market Idx Inv | 420800 | 1.30% | 4500 | 1.08% | 2018-07-31 |
| Vanguard Total Stock Mkt Idx | 714101 | 2.21% | -- | -- | 2018-07-31 |
| Driehaus Micro Cap Growth | 103965 | 0.32% | -10022 | -8.79% | 2018-07-31 |
| Vanguard Explorer Inv | 70546 | 0.22% | 70546 | -- | 2018-06-30 |
| JNL/Oppenheimer Global Growth B | 67194 | 0.21% | 67194 | -- | 2018-06-30 |
| Putnam Capital Opportunities A | 123683 | 0.43% | -60894 | -32.99% | 2018-03-31 |
| Putnam Global Health Care A | 459534 | 1.58% | -167019 | -26.66% | 2018-03-31 |
| iShares Micro-Cap | 47502 | 0.18% | -- | -- | 2018-07-26 |
| ALPS Medical Breakthroughs ETF | 44672 | 0.18% | -- | -- | 2018-07-27 |
| BlackRock Extended Equity Market K | 49566 | 0.15% | 7300 | 17.27% | 2018-06-30 |
| Royce Micro Cap Trust | 61100 | 0.21% | -60000 | -49.55% | 2018-03-31 |
| Vanguard Health Care ETF | 37875 | 0.13% | 37875 | -- | 2018-05-31 |
| BioShares | 44105 | 0.16% | -- | -- | 2018-06-14 |
| Putnam VT Global Health Care IA | 48500 | 0.17% | -15734 | -24.49% | 2018-03-31 |
| DFA US Small Cap I | 38591 | 0.13% | -- | -- | 2018-03-31 |
| Vanguard Instl Ttl Stk Mkt Idx InstlPls | 35713 | 0.12% | -3287 | -8.43% | 2018-03-31 |
| DFA US Targeted Value I | 31656 | 0.11% | -- | -- | 2018-02-28 |
| DFA US Core Equity 2 I | 33499 | 0.12% | -- | -- | 2018-02-28 |
| Vanguard Balanced Index Inv | 20700 | 0.07% | -- | -- | 2018-02-28 |
| Putnam Small Cap Growth A | 21556 | 0.09% | 15661 | 265.67% | 2017-12-31 |
| iShares Core S&P Total US Stock Mkt | 7553 | 0.04% | 26 | 0.35% | 2018-01-30 |
| BNY Mellon EB DL Mkt Completion | 15167 | 0.06% | 1697 | 12.60% | 2017-12-31 |
| DFA Tax-Managed US Small Cap | 9732 | 0.04% | -- | -- | 2017-11-30 |
| AMG Managers Special Equity Service | 13785 | 0.05% | -- | -- | 2017-11-30 |
| BNY Mellon Market Completion Fund UC1 | 13470 | 0.05% | 12862 | 2115.46% | 2017-09-30 |
| CREF Stock R1 | 52840 | 0.27% | -- | -- | 2016-12-31 |
| Northern Trust Russell 2000 Index Fund - DC - Non-Lending | 31248 | 0.16% | 229 | 0.74% | 2016-12-31 |
| The Vanguard Russell 2000 Growth Index | 19903 | 0.10% | -- | -- | 2016-12-31 |
| JNL/Mellon Capital Healthcare Sector B | 14088 | 0.07% | -- | -- | 2016-09-30 |
| Schwab Small Cap Index | 18048 | 0.09% | -- | -- | 2016-12-31 |
| AXA 2000 Managed Volatility K | 15689 | 0.08% | -- | -- | 2016-11-30 |
| BlackRock Russell 2000 | 16425 | 0.08% | 912 | 5.88% | 2016-12-31 |
| EQ/Small Company Index IA | 13800 | 0.07% | -- | -- | 2016-11-30 |
| TIAA-CREF Small-Cap Blend Idx Inst | 14056 | 0.07% | -- | -- | 2016-12-31 |
| Fidelity® Advisor Small Cap Opps Fund | 585269 | 3.60% | -173700 | -22.90% | 2015-07-31 |
| Franklin Biotechnology Discovery | 503646 | 3.10% | -- | -- | 2015-07-31 |
| Fidelity Advisor® Health Care Fund | 274000 | 1.40% | -- | -- | 2015-09-30 |
| iShares Russell 2000 (AU) | 183792 | 1.10% | -117 | -0.10% | 2015-11-18 |
| DWS Biotech | 180000 | 0.80% | -- | -- | 2015-09-30 |
| Fidelity® Contrafund® Fund | 172900 | 0.90% | 172900 | -- | 2015-09-30 |
| Fidelity® Small Cap Growth Fund | 169700 | 1.00% | -- | -- | 2015-07-31 |
| Fidelity® Stock Selector Small Cap Fund | 158506 | 1.00% | -42900 | -21.30% | 2015-07-31 |
| Fidelity® Blue Chip Growth Fund | 148440 | 0.80% | 148440 | -- | 2015-09-30 |
| Fidelity® Select Health Care Portfolio | 900000 | 4.70% | -- | -- | 2015-09-30 |
| Fidelity VIP Health Care Portfolio | 120000 | 0.60% | -- | -- | 2015-09-30 |
| Faheem Hasnain | Founder of Gossamer Bio, Inc., Faheem Hasnain is a businessperson who has been at the head of 10 different companies and currently occupies the position of Non-Executive Chairman for Gossamer Bio, Inc., Chairman for Mirati Therapeutics, Inc., Chairman at SENT�0�1‰, Inc. (California) and Chairman of Tocagen, Inc. He is also on the board of Kura Oncology, Inc. and Member-Overseers Board at The Scripps Research Institute. In his past career he was President, Chief Executive Officer & Director at PDL BioPharma, Inc., Executive Vice President of Biogen, Inc. and EVP-Oncology & Rheumatology Strategic Business Unit at Biogen Idec, Inc. (North Carolina) (a subsidiary of Biogen, Inc.), President-Oncology Therapeutics Network at Bristol-Myers Squibb Co., Vice President-Global eBusiness at GlaxoSmithKline Plc, Chairman at Vital Therapies, Inc., Chairman at Ambit Biosciences Corp., President, Chief Executive Officer & Director at Receptos LLC, President, Chief Executive Officer & Director at Abbott Biotherapeutics Corp. and President for Oncology Therapeutics Network Corp. Mr. Hasnain received an undergraduate degree from the University of Windsor. |
|---|---|
| Jamie A. Donadio | Jamie A. Donadio is Chief Financial Officer & Senior Vice President at Mirati Therapeutics, Inc. In the past Mr. Donadio held the position of Senior Director-Finance at Amylin Pharmaceuticals, Inc. and Senior Accountant at Novatel Wireless, Inc. He received an undergraduate degree from Babson College. |
| Bruce Leonard Andrews Carter | Bruce Leonard Andrews Carter is a businessperson who has been at the head of 7 different companies. Presently, he holds the position of Non-Executive Chairman at Enanta Pharmaceuticals, Inc. He is also on the board of Dr. Reddy's Laboratories Ltd., Mirati Therapeutics, Inc., Aurigene Discovery Technologies Ltd. and Navigating Cancer, Inc. and Chairman of Global Alliance for TB Drug Development and Professor at the University of Washington. In his past career Bruce Leonard Andrews Carter was Chairman for Xencor, Inc., Chairman for Infectious Disease Research Institute, Executive Chairman of Infectious Disease Research Institute, Chief Scientific Officer & Executive VP at Novo Nordisk A, Chairman at ZymoGenetics, Inc., Executive Chairman at Immune Design Corp., Head-Molecular Genetics at G.D. Searle & Co., Inc. and Director at McAdams Wright Ragen, Inc. He received an undergraduate degree from The University of Nottingham and a doctorate from Queen Elizabeth College. |
| Henry J. Fuchs | Henry J. Fuchs holds the position of President-Worldwide Research & Development at BioMarin Pharmaceutical, Inc. He is also on the board of Genomic Health, Inc. and Mirati Therapeutics, Inc. In the past Dr. Fuchs occupied the position of Independent Director at Ardea Biosciences, Inc., Chief Medical Officer & Executive Vice President at Onyx Pharmaceuticals, Inc. and Principal at Genentech, Inc. Henry J. Fuchs received a doctorate from George Washington University and an undergraduate degree from Harvard University. |
| Michael G. Grey | Founder of Mirum Pharmaceuticals, Inc., Lumena Pharmaceuticals, Inc. and Reneo Pharmaceuticals, Inc., Michael G. Grey is an entrepreneur and businessperson who has been the head of 14 different companies and currently is Executive Chairman of Amplyx Pharmaceuticals, Inc., Executive Chairman for Reneo Pharmaceuticals, Inc., Executive Chairman of Spruce Biosciences, Inc., Executive Chairman for Mirum Pharmaceuticals, Inc. and Venture partner at Pappas Capital LLC. Michael G. Grey is also on the board of 7 other companies. In the past Mr. Grey held the position of President & Chief Operating Officer for Ansan, Inc., Independent Director at Ziarco Pharma Ltd., Executive Chairman for Ziarco Group Ltd., Non-Executive Chairman for IDM Pharma, Inc., President, Chief Executive Officer & Director at Lumena Pharmaceuticals, Inc., President, Chief Executive Officer & Director at Trega Biosciences, Inc., President & Chief Executive Officer at SGX Pharmaceuticals, Inc., President & Chief Operating Officer of Ansan Pharmaceuticals, Inc., President of Biochem Therapeutic, Inc., President & Chief Executive Officer for Auspex Pharmaceuticals, Inc., Vice President-Corporate Development of Glaxo, Inc. and Vice President-Corporate Development of Glaxo Holdings Plc. He received an undergraduate degree from The University of Nottingham. |
| Julie Michele Cherrington | Dr. Julie M. Cherrington is a President, Chief Executive Officer & Director at Arch Oncology, Inc., a Member at American Diabetes Association, a Member at American Society of Clinical Oncology and a Member at American Society of Hematology. She is on the Board of Directors at QUE Oncology, Inc., Mirati Therapeutics, Inc. and Arch Oncology, Inc. Dr. Cherrington was previously employed as a President, Chief Executive Officer & Director by Pathway Therapeutics Ltd., a President, Chief Executive Officer & Director by Pathway Therapeutics, Inc., an Independent Non-Executive Director by Progen Pharmaceuticals Ltd., an Independent Non-Executive Director by ChemGenex Pharmaceuticals Pty Ltd., a President by Phenomix Australia Pty Ltd., a President by Phenomix Corp., a VP-Preclinical Research & Exploratory Development by SUGEN, Inc., a Member by American Association for Cancer Research, a Virology Director by Gilead Sciences, Inc., and a Chairman by Xenome Ltd. She received her undergraduate degree from the University of California, Davis, a graduate degree from the University of California, Davis and a doctorate degree from the University of Minnesota. |
| Craig A. Johnson | Craig A. Johnson is on the board of Heron Therapeutics, Inc., La Jolla Pharmaceutical Co., Mirati Therapeutics, Inc. and Odonate Therapeutics, Inc. In the past Mr. Johnson occupied the position of Chief Financial Officer, Secretary & Senior VP at NovaDel Pharma, Inc., Chief Financial Officer for PURE Bioscience, Inc., President for Philip Morris USA, Inc., Chief Financial Officer & Senior VP-Operations at MitoKor, Inc., Chief Financial Officer & Vice President of TorreyPines Therapeutics, Inc., Chief Financial Officer & Vice President of TPTX, Inc. and Vice President of Horizon Pharmaceutical LLC. He received an undergraduate degree from The University of Michigan-Dearborn. |
| Christopher C. LeMasters | Founder of Cabrellis Pharmaceuticals Corp., Adastra Pharmaceuticals, Inc., Aarden Pharmaceuticals, Inc. and Hoosier Oncology Group, Inc., Christopher C. LeMasters is an entrepreneur is on the board of Promosome LLC (former Chief Executive Officer & Director) and Hoosier Oncology Group, Inc. and Chief Business Officer & Executive Vice President at Mirati Therapeutics, Inc. Mr. LeMasters previously was Chief Business Officer at Adastra Pharmaceuticals, Inc., Auditor of Owens Corning, Principal at Eli Lilly & Co., Vice President-Business Development of Conforma Therapeutics Corp., Chief Business Officer for Cabrellis Pharmaceuticals Corp., Consultant at Coopers & Lybrand Consulting, Inc. and Director at Aarden Pharmaceuticals, Inc. Mr. LeMasters received an undergraduate degree from Indiana University and an MBA from The University of Chicago. |
| Michael G. Grey | Founder of Mirum Pharmaceuticals, Inc., Lumena Pharmaceuticals, Inc. and Reneo Pharmaceuticals, Inc., Michael G. Grey is an entrepreneur and businessperson who has been the head of 14 different companies and currently is Executive Chairman of Amplyx Pharmaceuticals, Inc., Executive Chairman for Reneo Pharmaceuticals, Inc., Executive Chairman of Spruce Biosciences, Inc., Executive Chairman for Mirum Pharmaceuticals, Inc. and Venture partner at Pappas Capital LLC. Michael G. Grey is also on the board of 7 other companies. In the past Mr. Grey held the position of President & Chief Operating Officer for Ansan, Inc., Independent Director at Ziarco Pharma Ltd., Executive Chairman for Ziarco Group Ltd., Non-Executive Chairman for IDM Pharma, Inc., President, Chief Executive Officer & Director at Lumena Pharmaceuticals, Inc., President, Chief Executive Officer & Director at Trega Biosciences, Inc., President & Chief Executive Officer at SGX Pharmaceuticals, Inc., President & Chief Operating Officer of Ansan Pharmaceuticals, Inc., President of Biochem Therapeutic, Inc., President & Chief Executive Officer for Auspex Pharmaceuticals, Inc., Vice President-Corporate Development of Glaxo, Inc. and Vice President-Corporate Development of Glaxo Holdings Plc. He received an undergraduate degree from The University of Nottingham. |
| Reed Vickerman | Mr. Reed Vickerman is Chief Operating Officer at Everyone Counts, Inc. Mr. Vickerman was previously employed as Chairman by San Diego Data Processing Corp., Vice President-Corporate Operations by Amylin Pharmaceuticals, Inc., Chief Operating & Financial Officer by San Diego Museum of Art, a Director-Information Technology by Advanced Tissue Sciences, Inc., a Principal by PricewaterhouseCoopers LLP, a Principal by Hewlett-Packard Co., Senior Director-Information Technology by Dura Pharmaceuticals, Inc., and Vice President-Information Technology & Facilities by Copper Mountain Networks, Inc. He received his undergraduate degree from Carnegie Mellon University. |
| Perry C. Johnston | Currently, Perry C. Johnston holds the position of Secretary, VP, Chief Legal & Compliance Officer at Mirati Therapeutics, Inc. He previously occupied the position of Principal at Jostens, Inc., Secretary, Vice President & General Counsel at Advanced BioEnergy LLC, Secretary, Vice President & General Counsel at Nevada Cancer Institute, Senior Legal Counsel at Medtronic, Inc., Senior Director-Legal at Amylin Pharmaceuticals, Inc., Vice President-Legal & Compliance at Cardionet LLC and Vice President-Legal, Regulatory & Compliance at Aperio Technologies, Inc. Perry C. Johnston received a graduate degree from The University of Minnesota Law School and an undergraduate degree from The Curtis L. Carlson School of Management. |
| Neil A. Reisman | Neil A. Reisman is a businessperson who has been the head of 6 different companies. Mr. Reisman occupies the position of Chairman of Nucleus Biologics, President, CEO, Manager & Assistant Secretary at Ficus Investments LLC, President & Director at RPFG Holdings, Inc., President for Lumenta Products LLC, President & Director at Tavistock Capital Group, Inc. and Managing Director & Director at Tavistock Group, Inc., President & Director at RoundPoint Financial Group, Inc. and Vice President & Assistant Secretary at RoundPoint Mortgage Co. (both are subsidiaries of Tavistock Group, Inc.). He is also on the board of Australian Agricultural Co. Ltd. and Mirati Therapeutics, Inc. and Manager of Baycorp Grec LLC, Vice President & Assistant Secretary at RoundPoint Mortgage Co., Manager at Biloxi Capital LLC, Manager for Tavistock Genome LLC and Manager of US Property & Financial Services LLC. In his past career he occupied the position of Chief Operating Officer for Kalypsys, Inc., Principal at Arthur Andersen LLP, CFO, Chief Operating Officer & General Counsel at CovX Research LLC, Principal at Borg Warner Security Corp., Principal at Amoco Corp. and Principal at Comdisco, Inc. Neil A. Reisman received an undergraduate degree from the University of Illinois and a graduate degree from the University of Pennsylvania. |
| Claire S. Padgett | Claire S. Padgett is Senior Vice President-Clinical Operations at Mirati Therapeutics, Inc. Dr. Padgett previously was Vice President-Clinical Operations at Cylene Pharmaceuticals, Inc., Vice President-Clinical Operations at Oncolytics Biotech, Inc., Vice President-Clinical Operations at Mast Therapeutics, Inc. and Executive Director-Clinical Operations at Conforma Therapeutics Corp. Dr. Padgett received a graduate degree and an MBA from Seton Hall University, an undergraduate degree from Rutgers State University of New Jersey and a doctorate from Capella University, Inc. |
| Henry J. Fuchs | Henry J. Fuchs holds the position of President-Worldwide Research & Development at BioMarin Pharmaceutical, Inc. He is also on the board of Genomic Health, Inc. and Mirati Therapeutics, Inc. In the past Dr. Fuchs occupied the position of Independent Director at Ardea Biosciences, Inc., Chief Medical Officer & Executive Vice President at Onyx Pharmaceuticals, Inc. and Principal at Genentech, Inc. Henry J. Fuchs received a doctorate from George Washington University and an undergraduate degree from Harvard University. |
| Charles M. Baum | Currently, Charles M. Baum holds the position of President, Chief Executive Officer & Director at Mirati Therapeutics, Inc. Dr. Baum is also on the board of Immunomedics, Inc. and Array BioPharma, Inc. In the past he was Senior VP & Head-Clinical Research at Pfizer Inc. Charles M. Baum received a doctorate from Washington University School of Medicine. |
| Isan Chen | Isan Chen occupies the position of EVP, Chief Medical & Development Officer at Mirati Therapeutics, Inc. In the past he occupied the position of Assistant Professor at Anderson Cancer Center, Vice President-Tumor Strategy at Pfizer Inc. and Chief Medical Officer of Aragon Pharmaceuticals, Inc. |
| James G. Christensen | James G. Christensen holds the position of Chief Scientific Officer & Executive VP at Mirati Therapeutics, Inc. He previously held the position of Senior Director-Oncology Precision Medicine at Pfizer Inc. Dr. Christensen received a doctorate from North Carolina State University. |
| Jessica M. Corson | Jessica M. Corson is Senior Director-Business Development at Mirati Therapeutics, Inc. |
| Temre Johnson | Temre Johnson holds the position of Director-Investor Relations & Communications at Mirati Therapeutics, Inc. |
| Aaron I. Davis | Aaron I. Davis founded Boxer Capital LLC. Presently, he is Executive Chairman at CiVi Biopharma, Inc. and Chief Executive Officer of Boxer Capital LLC. Mr. Davis is also on the board of Mirati Therapeutics, Inc., Sojournix, Inc. and Odonate Therapeutics, Inc. Mr. Davis previously held the position of Principal at UBS Securities LLC and Vice President of Tavistock Life Sciences Co. Aaron I. Davis received a graduate degree from Columbia University and an undergraduate degree from Emory University. |
| Maya Martinez-Davis | Maya Martinez-Davis is on the board of Mirati Therapeutics, Inc. and President-Biopharma Latin America at Merck KGaA. She received an undergraduate degree from St. Louis University and a graduate degree from Instituto de Empresa SL. |
abu_quant
扫一扫关注阿布量化
热门推荐
全部评论 0
暂无评论